Kraig Biocraft (KBLB) plans to double genetic insertions

Kraig Biocraft Laboratories, Inc. (OTCBB: KBLB) skyrocketed 861 percent to 25 cents per share, from Tuesday’s closing price of two-and-a-half cents per share, after the company announced it is gearing up to double the number of genetic insertions performed. The company specializes in the commercialization of new textiles and high performance fibers, and is working to develop high performance polymers using spider silk gene sequences.

Earlier this month, Kraig announced that its scientific team had recently succeeded in building eight unique DNA constructs, specifically targeted for the production of new fusion silk proteins, which the team is preparing for genetic insertion over the next few weeks. Kraig anticipates that the rate of DNA construct insertions in May will be double that which has been performed to date.

CEO Kim Thompson commented on this breakthrough, “We are now entering the next phase in which the team is reallocating recourses to genetic insertion. This is directly related to our recent development of new DNA constructs that are specifically targeted for the production of new fusion silk proteins. We intend to dramatically ramp up the number of insertions performed in order to gain the maximum benefit from the new insertion packets.”

The goal of these genetic insertions is the mass production of spider silk, known for its incredible tensile strength, and stronger than steel by weight. Kraig hopes to tap into, and dominate the $92 billion high performance fiber industry.

In 2007 Kraig Biocraft Laboratories signed an intellectual property and collaborative research agreement with the University of Notre Dame. Since that time the Company has been a proud sponsor of scientific research and development within the university.